리듬 파마슈티컬스(RYTM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $115.48 (-0.47%), 시가총액 $6.12B, 52주 범위 $59.18 ~ $117.62.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency
리듬 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
리듬 파마슈티컬스의 현재 주가는 $115.48 (-0.47%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
리듬 파마슈티컬스의 시가총액은 약 $6.12B입니다.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate i